

Supplementary Table 2. Subgroup analysis of the risk of AAA classified by CKD stage

Subgroup	CKD stage	No. of patients	AAA events	Person-year	AAA incidence ^{a)}	HR (95% CI)	P for interaction
Sex							
Male	Stage 1	2,766,668	2,799	25,602,866.05	0.11	1 (Ref)	<0.001
	Stage 2	2,231,273	6,754	20,368,616.94	0.33	1.14 (1.09–1.20)	
	Stage ≥3	430,958	4,269	3,532,629.85	1.21	1.29 (1.21–1.37)	
Female	Stage 1	1,322,059	833	12,291,889.12	0.07	1 (Ref)	
	Stage 2	2,400,281	3,123	22,303,507.46	0.14	1.02 (0.94–1.10)	
	Stage ≥3	787,090	2,982	7,026,210.02	0.42	0.95 (0.87–1.03)	
Age group							
<65 yr	Stage 1	4,022,257	3,146	37,306,739.58	0.08	1 (Ref)	<0.001
	Stage 2	4,095,937	5,794	37,958,482.90	0.15	1.117 (1.066–1.171)	
	Stage ≥3	525,127	1,277	4,828,575.29	0.26	1.329 (1.237–1.429)	
≥65 yr	Stage 1	66,470	486	588,015.59	0.83	1 (Ref)	
	Stage 2	535,617	4,083	4,713,641.50	0.87	1.01 (0.92–1.11)	
	Stage ≥3	692,921	5,974	5,730,264.59	1.04	1.02 (0.93–1.13)	
Smoking							
Nonsmoker	Stage 1	2,026,664	1,458	18,827,912.42	0.08	1 (Ref)	<0.001
	Stage 2	3,015,424	4,735	27,919,985.20	0.17	0.99 (0.93–1.05)	
	Stage ≥3	931,362	4,043	8,196,792.55	0.49	0.95 (0.88–1.01)	
Ex-smoker	Stage 1	621,579	707	5,756,629.64	0.12	1 (Ref)	
	Stage 2	630,519	1,964	5,771,058.40	0.34	1.10 (1.01–1.20)	
	Stage ≥3	131,958	1,345	1,091,665.43	1.23	1.28 (1.16–1.41)	
Current smoker	Stage 1	1,440,484	1,467	13,310,213.12	0.11	1 (Ref)	
	Stage 2	985,611	3,178	8,981,080.80	0.35	1.26 (1.18–1.35)	
	Stage ≥3	154,728	1,863	1,270,381.90	1.47	1.50 (1.38–1.62)	
Diabetes mellitus							
No	Stage 1	3,820,900	3,222	35,450,080.68	0.09	1 (Ref)	0.724
	Stage 2	4,234,861	8,641	39,117,412.98	0.22	1.12 (1.07–1.17)	
	Stage ≥3	1,027,651	6,214	9,005,699.73	0.69	1.17 (1.11–1.24)	
Yes	Stage 1	267,827	410	2,444,674.50	0.17	1 (Ref)	
	Stage 2	396,693	1,236	3,554,711.43	0.35	1.09 (0.98–1.22)	
	Stage ≥3	190,397	1,037	1,553,140.15	0.67	1.12 (0.99–1.26)	
Hypertension							
No	Stage 1	3,275,407	1,897	30,415,509.93	0.06	1 (Ref)	0.217
	Stage 2	3,395,590	4,187	31,443,392.69	0.13	1.13 (1.06–1.19)	
	Stage ≥3	619,155	2,182	5,512,625.71	0.40	1.21 (1.13–1.31)	
Yes	Stage 1	813,320	1,735	7,479,245.24	0.23	1 (Ref)	
	Stage 2	1,235,964	5,690	11,228,731.71	0.51	1.10 (1.04–1.17)	
	Stage ≥3	598,893	5,069	5,046,214.16	1.00	1.13 (1.06–1.21)	
Hyperlipidemia							
No	Stage 1	3,526,792	2,644	32,703,754.61	0.08	1 (Ref)	0.032
	Stage 2	3,802,561	6,793	35,058,065.89	0.19	1.11 (1.06–1.17)	
	Stage ≥3	883,421	4,557	7,644,316.14	0.60	1.13 (1.06–1.20)	
Yes	Stage 1	561,935	988	5,191,000.56	0.19	1 (Ref)	
	Stage 2	828,993	3,084	7,614,058.52	0.41	1.12 (1.04–1.20)	
	Stage ≥3	334,627	2,694	2,914,523.74	0.92	1.23 (1.13–1.33)	

Supplementary Table 2. Continued

Subgroup	CKD stage	No. of patients	AAA events	Person-year	AAA incidence ^{a)}	HR (95% CI)	P for interaction
Proteinuria							
Negative or trace	Stage 1	4,006,151	3,496	37,135,993.02	0.09	1 (Ref)	0.023
	Stage 2	4,522,194	9,492	41,683,154.50	0.23	1.12 (1.07–1.17)	
	Stage ≥3	1,159,287	6,699	10,085,728.58	0.66	1.15 (1.09–1.22)	
≥1+	Stage 1	82,576	136	758,762.15	0.18	1 (Ref)	
	Stage 2	109,360	385	988,969.90	0.39	1.05 (0.86–1.27)	
	Stage ≥3	58,761	552	473,111.29	1.17	1.30 (1.07–1.57)	

Adjusted for age, sex, smoking, alcohol consumption, regular exercise stroke, DM, hypertension, hyperlipidemia, myocardial infarction, chronic obstructive pulmonary disease, body mass index, and urine protein (model 6).

AAA, abdominal aortic aneurysm; CKD, chronic kidney disease; HR, hazard ratio, CI, confidence interval; Ref, reference.

^{a)}Per 1,000 person-years.